GenomeDx Biosciences has secured an undisclosed amount in a Series B round of financing led by Merck Global Health Innovation Fund. The San Diego company will use the funding to support commercial growth of its Decipher test, designed to predict a patient's risk of developing prostate cancer.

Related Summaries